Sigrid Therapeutics, a Stockholm, Sweden-based health-tech startup, raised $8.4M in funding.
US VC fund Joyance was joined by several Swedish family offices, including Hans and Barbara Bergström, the Mattsson family, Crosslight Partners and Irrus Investments.
The round brought the total since inception of $17.5m.
The company intends to use the funds to coduct clinical studies that will form the basis for CE marking in the EU.
Led by CEO Sana Alajmovic, Sigrid Therapeutics is a clinical-stage health-tech company pioneering a new class of therapies for blood sugar control, to prevent and treat type 2 diabetes and its related chronic lifestyle diseases.